KEYMED BIO-B Reports Unchanged Share Capital and Confirms Public Float Compliance for March 2026

Bulletin Express04-01

Keymed Biosciences Inc. (KEYMED BIO-B) has released its Monthly Return for Equity Issuer covering the period ended 31 March 2026, indicating a stable capital structure and adherence to Hong Kong Listing Rule public-float requirements.

Authorised Share Capital • Total authorised shares remained at 500.00 million ordinary shares with a par value of USD 0.0001 each, keeping authorised capital steady at USD 50,000. No changes were recorded during the month.

Issued Shares and Treasury Position • Issued shares (excluding treasury shares) stood unchanged at 298.74 million. • The company held no treasury shares, and there were no issuances, cancellations, conversions, or repurchases during March.

Public Float Status • Keymed confirmed compliance with the Main Board’s minimum public-float threshold of 25% of issued shares as of 31 March 2026.

Corporate Actions • The company reported no movements related to share options, warrants, convertible securities, or other equity-linked instruments.

Governance Confirmation • The filing was authorised and submitted by Executive Director Dr. Bo Chen on 1 April 2026.

Overall, Keymed’s March return reflects a month of capital stability, with no dilution events and full compliance with Hong Kong Exchange regulations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1168735452?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 16:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168735452","market":"hk","top_or_hot":-1,"title":"KEYMED BIO-B Reports Unchanged Share Capital and Confirms Public Float Compliance for March 2026","media":"Bulletin Express","content":"<p>Keymed Biosciences Inc. (KEYMED BIO-B) has released its Monthly Return for Equity Issuer covering the period ended 31 March 2026, indicating a stable capital structure and adherence to Hong Kong Listing Rule public-float requirements.</p>\n<p>Authorised Share Capital  \n• Total authorised shares remained at 500.00 million ordinary shares with a par value of USD 0.0001 each, keeping authorised capital steady at USD 50,000. No changes were recorded during the month.</p>\n<p>Issued Shares and Treasury Position  \n• Issued shares (excluding treasury shares) stood unchanged at 298.74 million.  \n• The company held no treasury shares, and there were no issuances, cancellations, conversions, or repurchases during March.</p>\n<p>Public Float Status  \n• Keymed confirmed compliance with the Main Board’s minimum public-float threshold of 25% of issued shares as of 31 March 2026.</p>\n<p>Corporate Actions  \n• The company reported no movements related to share options, warrants, convertible securities, or other equity-linked instruments.</p>\n<p>Governance Confirmation  \n• The filing was authorised and submitted by Executive Director Dr. Bo Chen on 1 April 2026.</p>\n<p>Overall, Keymed’s March return reflects a month of capital stability, with no dilution events and full compliance with Hong Kong Exchange regulations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>KEYMED BIO-B Reports Unchanged Share Capital and Confirms Public Float Compliance for March 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKEYMED BIO-B Reports Unchanged Share Capital and Confirms Public Float Compliance for March 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-01 16:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Keymed Biosciences Inc. (KEYMED BIO-B) has released its Monthly Return for Equity Issuer covering the period ended 31 March 2026, indicating a stable capital structure and adherence to Hong Kong Listing Rule public-float requirements.</p>\n<p>Authorised Share Capital  \n• Total authorised shares remained at 500.00 million ordinary shares with a par value of USD 0.0001 each, keeping authorised capital steady at USD 50,000. No changes were recorded during the month.</p>\n<p>Issued Shares and Treasury Position  \n• Issued shares (excluding treasury shares) stood unchanged at 298.74 million.  \n• The company held no treasury shares, and there were no issuances, cancellations, conversions, or repurchases during March.</p>\n<p>Public Float Status  \n• Keymed confirmed compliance with the Main Board’s minimum public-float threshold of 25% of issued shares as of 31 March 2026.</p>\n<p>Corporate Actions  \n• The company reported no movements related to share options, warrants, convertible securities, or other equity-linked instruments.</p>\n<p>Governance Confirmation  \n• The filing was authorised and submitted by Executive Director Dr. Bo Chen on 1 April 2026.</p>\n<p>Overall, Keymed’s March return reflects a month of capital stability, with no dilution events and full compliance with Hong Kong Exchange regulations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02162","symbol_name":"康诺亚-B","start_time":0,"source_url":"","article_id":"1168735452","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168735452","pubTimestamp":1775033238,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Keymed Biosciences Inc. (KEYMED BIO-B) has released its Monthly Return for Equity Issuer covering the period ended 31 March 2026, indicating a stable capital structure and adherence to Hong Kong...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02162":"康诺亚-B"},"translate_title":"KEYMED BIO-B报告股本不变并确认2026年3月公众持股量合规性","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":1},"content_text":"Keymed Biosciences Inc. (KEYMED BIO-B) has released its Monthly Return for Equity Issuer covering the period ended 31 March 2026, indicating a stable capital structure and adherence to Hong Kong Listing Rule public-float requirements.\nAuthorised Share Capital  \n• Total authorised shares remained at 500.00 million ordinary shares with a par value of USD 0.0001 each, keeping authorised capital steady at USD 50,000. No changes were recorded during the month.\nIssued Shares and Treasury Position  \n• Issued shares (excluding treasury shares) stood unchanged at 298.74 million.  \n• The company held no treasury shares, and there were no issuances, cancellations, conversions, or repurchases during March.\nPublic Float Status  \n• Keymed confirmed compliance with the Main Board’s minimum public-float threshold of 25% of issued shares as of 31 March 2026.\nCorporate Actions  \n• The company reported no movements related to share options, warrants, convertible securities, or other equity-linked instruments.\nGovernance Confirmation  \n• The filing was authorised and submitted by Executive Director Dr. Bo Chen on 1 April 2026.\nOverall, Keymed’s March return reflects a month of capital stability, with no dilution events and full compliance with Hong Kong Exchange regulations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1168735452","isCrawlerRequest":true}